Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Hisamitsu Pharmaceutical Co., Inc. (HPX.F)

Compare
26.80
-0.40
(-1.47%)
As of 8:12:50 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
2/29/2024
2/28/2023
2/28/2022
2/28/2021
Total Revenue
150,185,000
141,706,000
128,330,000
120,193,000
114,510,000
Cost of Revenue
65,452,000
62,735,000
55,630,000
50,126,000
45,337,000
Gross Profit
84,732,000
78,970,000
72,699,000
70,067,000
69,173,000
Operating Expense
70,955,000
65,803,000
61,099,000
60,730,000
58,501,000
Operating Income
13,777,000
13,167,000
11,600,000
9,337,000
10,672,000
Net Non Operating Interest Income Expense
2,870,000
2,546,000
879,000
133,000
553,000
Pretax Income
20,649,000
19,186,000
16,113,000
12,956,000
12,197,000
Tax Provision
5,487,000
4,754,000
3,987,000
3,093,000
2,764,000
Net Income Common Stockholders
14,650,000
13,969,000
11,742,000
9,658,000
9,250,000
Diluted NI Available to Com Stockholders
14,650,000
13,969,000
11,742,000
9,658,000
9,250,000
Basic EPS
195.99
181.62
148.01
118.92
113.22
Diluted EPS
195.74
181.42
147.88
118.84
113.11
Basic Average Shares
75,141.05
76,918.55
79,340.06
81,213
81,707
Diluted Average Shares
75,232.89
76,998.13
79,402.22
81,268.93
81,778.80
Total Operating Income as Reported
13,777,000
13,167,000
11,599,000
9,337,000
10,671,000
Total Expenses
136,407,000
128,538,000
116,729,000
110,856,000
103,838,000
Net Income from Continuing & Discontinued Operation
14,650,000
13,969,000
11,742,000
9,658,000
9,250,000
Normalized Income
13,290,860.96
14,353,272
11,705,103
9,415,241
9,154,148
Interest Income
2,897,000
2,564,000
894,000
153,000
563,000
Interest Expense
27,000
18,000
15,000
20,000
10,000
Net Interest Income
2,870,000
2,546,000
879,000
133,000
553,000
EBIT
20,676,000
19,204,000
16,128,000
12,976,000
12,207,000
EBITDA
26,364,000
24,376,000
21,080,000
17,297,000
16,286,000
Reconciled Cost of Revenue
65,452,000
62,735,000
55,630,000
50,126,000
45,337,000
Reconciled Depreciation
5,688,000
5,172,000
4,952,000
4,321,000
4,079,000
Net Income from Continuing Operation Net Minority Interest
14,650,000
13,969,000
11,742,000
9,658,000
9,250,000
Total Unusual Items Excluding Goodwill
1,851,000
-511,000
49,000
319,000
124,000
Total Unusual Items
1,851,000
-511,000
49,000
319,000
124,000
Normalized EBITDA
24,513,000
24,887,000
21,031,000
16,978,000
16,162,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
491,860.96
-126,728
12,103
76,241
28,148
2/28/2021 - 7/14/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

UNICHEMLAB.NS Unichem Laboratories Limited
604.95
-2.62%
 
SHILPAMED.NS Shilpa Medicare Limited
610.10
-2.75%
 
APLLTD.NS Alembic Pharmaceuticals Limited
743.65
-4.18%
 
KNSA Kiniksa Pharmaceuticals International, plc
20.05
+2.14%
 
HCM HUTCHMED (China) Limited
16.30
-1.98%
 
ALKS Alkermes plc
33.92
-0.35%
 
ELAN Elanco Animal Health Incorporated
11.01
+0.78%
 
KMDA Kamada Ltd.
6.77
-2.10%